Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

被引：1
作者：
Cohen, Jonathan [1 ]
Palumbo, Alison [1 ]
Wing, Jason [1 ]
Heinrich, Michael C. [2 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Pharm Serv, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Portland VA Hlth Care Syst, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97201 USA
来源：
LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 10期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; INHIBITOR; IMATINIB; THERAPY;
D O I：
10.1080/10428194.2020.1768380
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2511 / 2514
页数：4
相关论文
共 14 条
[1]  
[Anonymous], 2016, ICL PACK INS
[2]  
Chelysheva E, 2018, HAEMATOLOGICA
[3]   Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis [J].
Chen, Kang-kang ;
Du, Tai-feng ;
Xiong, Pei-sheng ;
Fan, Guan-hua ;
Yang, Wei .
FRONTIERS IN ONCOLOGY, 2019, 9
[4]   Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors [J].
Chopade, Pradnya ;
Akard, Luke P. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (11) :710-723
[5]   Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial [J].
Cortes, Jorge E. ;
Kim, Dong-Wook ;
Pinilla-Ibarz, Javier ;
le Coutre, Philipp D. ;
Paquette, Ronald ;
Chuah, Charles ;
Nicolini, Franck E. ;
Apperley, Jane F. ;
Khoury, H. Jean ;
Talpaz, Moshe ;
DeAngelo, Daniel J. ;
Abruzzese, Elisabetta ;
Rea, Delphine ;
Baccarani, Michele ;
Mueller, Martin C. ;
Gambacorti-Passerini, Carlo ;
Lustgarten, Stephanie ;
Rivera, Victor M. ;
Haluska, Frank G. ;
Guilhot, Francois ;
Deininger, Michael W. ;
Hochhaus, Andreas ;
Hughes, Timothy P. ;
Shah, Neil P. ;
Kantarjian, Hagop M. .
BLOOD, 2018, 132 (04) :393-404
[6]   Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias [J].
Cortes, Jorge E. ;
Kantarjian, Hagop ;
Shah, Neil P. ;
Bixby, Dale ;
Mauro, Michael J. ;
Flinn, Ian ;
O'Hare, Thomas ;
Hu, Simin ;
Narasimhan, Narayana I. ;
Rivera, Victor M. ;
Clackson, Tim ;
Turner, Christopher D. ;
Haluska, Frank G. ;
Druker, Brian J. ;
Deininger, Michael W. N. ;
Talpaz, Moshe .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (22) :2075-2088
[7]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[8]   Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia [J].
Engel, Nils W. ;
Constantin, Andre ;
Fowlkes, Sabrina ;
Assouline, Sarit .
JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (06) :592-U254
[9]   Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia [J].
Etienne, Gabriel ;
Guilhot, Joelle ;
Rea, Delphine ;
Rigal-Huguet, Francoise ;
Nicolini, Franck ;
Charbonnier, Aude ;
Guerci-Bresler, Agnes ;
Legros, Laurence ;
Varet, Bruno ;
Gardembas, Martine ;
Dubruille, Viviane ;
Tulliez, Michel ;
Noel, Marie-Pierre ;
Ianotto, Jean-Christophe ;
Villemagne, Bruno ;
Carre, Martin ;
Guilhot, Francois ;
Rousselot, Philippe ;
Mahon, Francois-Xavier .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (03) :298-+
[10]   Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring [J].
Jabbour, Elias ;
Kantarjian, Hagop .
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) :442-459
12